Connection

M ATASSI to Female

This is a "connection" page, showing publications M ATASSI has written about Female.
Connection Strength

0.400
  1. A proof-of-principle bite force study using two experimental test denture adhesives and a currently marketed denture adhesive. Clin Exp Dent Res. 2020 04; 6(2):266-273.
    View in: PubMed
    Score: 0.025
  2. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.021
  3. Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice. Autoimmunity. 2017 Aug; 50(5):293-305.
    View in: PubMed
    Score: 0.021
  4. Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules. J Neuroimmunol. 2017 05 15; 306:31-39.
    View in: PubMed
    Score: 0.020
  5. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.020
  6. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.019
  7. Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin. Immunobiology. 2014 Dec; 219(12):950-7.
    View in: PubMed
    Score: 0.017
  8. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.014
  9. T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients. Autoimmunity. 2012 Mar; 45(2):153-60.
    View in: PubMed
    Score: 0.014
  10. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Immunobiology. 2012 Jan; 217(1):1-7.
    View in: PubMed
    Score: 0.014
  11. Does Clostridium botulinum neurotoxin A exhibit molecular mimicry with thyroid autoantigens and cause thyroid complications in predisposed persons? Endocrine. 2011 Aug; 40(1):140-1; author reply 142-3.
    View in: PubMed
    Score: 0.014
  12. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.014
  13. Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States. Int J Immunogenet. 2011 Feb; 38(1):55-62.
    View in: PubMed
    Score: 0.013
  14. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
    View in: PubMed
    Score: 0.011
  15. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.010
  16. Subtle differences in HLA DQ haplotype-associated presentation of AChR alpha-chain peptides may suffice to mediate myasthenia gravis. Autoimmunity. 2006 Jun; 39(4):277-88.
    View in: PubMed
    Score: 0.010
  17. Use of alum and inactive Bordetella pertussis for generation of antibodies against synthetic peptides in mice. Immunol Invest. 2006; 35(2):137-48.
    View in: PubMed
    Score: 0.009
  18. Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. J Neuroimmunol. 2006 Feb; 171(1-2):8-16.
    View in: PubMed
    Score: 0.009
  19. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol Immunol. 2005 Aug; 42(12):1509-20.
    View in: PubMed
    Score: 0.009
  20. Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients. Autoimmunity. 2005 Mar; 38(2):161-9.
    View in: PubMed
    Score: 0.009
  21. Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor alpha-chain peptides: analysis in relation to age, thymic abnormality, and ethnicity. Hum Immunol. 2005 Jan; 66(1):32-42.
    View in: PubMed
    Score: 0.009
  22. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest. 2005; 34(2):119-42.
    View in: PubMed
    Score: 0.009
  23. T cells of mice treated with mPEG-myasthenogenic peptide conjugate are involved in protection against EAMG by stimulating lower pathogenic antibody responses. Autoimmunity. 2000; 32(1):45-55.
    View in: PubMed
    Score: 0.006
  24. B-cell activation in vitro by helper T cells specific to a protein region that is recognized both by T cells and by antibodies. Immunol Invest. 1998 May; 27(3):121-34.
    View in: PubMed
    Score: 0.006
  25. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol Immunol. 1997 Oct; 34(14):1031-40.
    View in: PubMed
    Score: 0.005
  26. Intersite helper function of T cells specific for a protein epitope that is not recognized by antibodies. Immunol Invest. 1997 Jun; 26(4):473-89.
    View in: PubMed
    Score: 0.005
  27. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest. 1997 Jun; 26(4):491-504.
    View in: PubMed
    Score: 0.005
  28. B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol. 1996 Oct 01; 157(7):3192-9.
    View in: PubMed
    Score: 0.005
  29. Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin. Vaccine. 1995 Jul; 13(10):927-32.
    View in: PubMed
    Score: 0.005
  30. Profile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol Immunol. 1994 Aug; 31(11):833-43.
    View in: PubMed
    Score: 0.004
  31. Mapping of the polypeptide chain organization of the main extracellular domain of the alpha-subunit in membrane-bound acetylcholine receptor by antipeptide antibodies spanning the entire domain. Adv Exp Med Biol. 1994; 347:221-8.
    View in: PubMed
    Score: 0.004
  32. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance. Adv Exp Med Biol. 1994; 347:65-75.
    View in: PubMed
    Score: 0.004
  33. Mapping the extracellular topography of the alpha-chain in free and in membrane-bound acetylcholine receptor by antibodies against overlapping peptides spanning the entire extracellular parts of the chain. J Protein Chem. 1994 Jan; 13(1):37-47.
    View in: PubMed
    Score: 0.004
  34. Autoimmune T-cell recognition sites of human thyrotropin receptor in Graves' disease. Mol Cell Endocrinol. 1993 Mar; 92(1):77-82.
    View in: PubMed
    Score: 0.004
  35. Profile of the regions on the alpha-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis. Mol Immunol. 1992 Dec; 29(12):1507-14.
    View in: PubMed
    Score: 0.004
  36. Localization and synthesis of an insulin-binding region on human insulin receptor. J Protein Chem. 1990 Apr; 9(2):229-33.
    View in: PubMed
    Score: 0.003
  37. Generation of species-specific antihemoglobin antibodies by immunization with synthetic peptides of human hemoglobin. J Protein Chem. 1989 Dec; 8(6):767-78.
    View in: PubMed
    Score: 0.003
  38. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol. 2006 Jun; 175(1-2):107-17.
    View in: PubMed
    Score: 0.002
  39. Preparation of monoclonal antibodies to preselected protein regions. Methods Enzymol. 1986; 121:69-95.
    View in: PubMed
    Score: 0.002
  40. Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8805-9.
    View in: PubMed
    Score: 0.002
  41. Genetic control of the immune response to myoglobin. XVI. Control of antibodies with preselected specificities following immunization with free synthetic peptides representing the antigenic sites or surface non-immunogenic locations in the protein. J Immunogenet. 1983 Dec; 10(6):453-64.
    View in: PubMed
    Score: 0.002
  42. Production of monoclonal antibodies with preselected submolecular binding specificities to protein antigenic sites: antibodies to sperm whale myoglobin sites. Mol Immunol. 1983 Jul; 20(7):719-26.
    View in: PubMed
    Score: 0.002
  43. Production of monoclonal antibodies with pre-selected submolecular binding specificities to protein determinants: demonstration with sperm whale myoglobin. Mol Immunol. 1982 Dec; 19(12):1699-1702.
    View in: PubMed
    Score: 0.002
  44. Genetic control of the immune response to myoglobin. VIII. Control of antibody affinity. J Immunogenet. 1981 Oct; 8(5):387-94.
    View in: PubMed
    Score: 0.002
  45. Evidence for cellular but not serologic cross-reactivity between keyhole limpet hemocyanin and sperm-whale myoglobin. Cell Immunol. 1979 Sep 01; 46(2):384-97.
    View in: PubMed
    Score: 0.002
  46. Differentiation of the contribution of the two subunits of lutropin to its in vivo activity. Biochim Biophys Acta. 1978 Mar 28; 533(1):257-62.
    View in: PubMed
    Score: 0.001
  47. Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor. Muscle Nerve. 1993 Dec; 16(12):1293-301.
    View in: PubMed
    Score: 0.001
  48. Enzymic and immunochemical properties of lysozyme. VII. Location of all the antigenic reactive regions. A new approach to study immunochemistry of tight proteins. Biochim Biophys Acta. 1973 Mar 23; 303(1):203-9.
    View in: PubMed
    Score: 0.001
  49. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor. Clin Immunol Immunopathol. 1993 Mar; 66(3):230-8.
    View in: PubMed
    Score: 0.001
  50. Characteristics of peptides which compete for presented antigen-binding sites on antigen-presenting cells. Eur J Immunol. 1990 May; 20(5):953-60.
    View in: PubMed
    Score: 0.001
  51. Genetic control of the immune response to haemoglobin. III. Variant A beta (bm12) but not Ae (D2.GD) Ia polypeptides alter immune responsiveness towards the alpha -subunit of human haemoglobin. J Immunogenet. 1981 Dec; 8(6):471-6.
    View in: PubMed
    Score: 0.000
  52. T cell clones reactive with sperm whale myoglobin. Isolation of clones with specificity for individual determinants on myoglobin. J Exp Med. 1981 Nov 01; 154(5):1342-56.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.